Molbio Diagnostics IPO
Updated 11 Sept 2026, 5:03 pm.
Minimum investment (Retail)
₹14,526
1 lot · 18 shares at the upper price band
Price band
₹807
Latest GMP
Not yet quoted
Est. listing price
—
Issue size
₹939.7 Cr
GMP history
Each point is a recorded observation from the scheduled data sync.
GMP is an unofficial, unregulated grey-market estimate — not a prediction of listing performance.
Issue details
- Board
- Mainboard
- Price band
- ₹807
- Issue size
- ₹939.7 Cr
- Lot size
- 18
- Opens
- 10 Aug 2026
- Closes
- 12 Aug 2026
- Allotment
- 13 Aug 2026
- Listing
- 17 Aug 2026
- Est. listing price
- —
- Listing price
- Awaited
- Listing gain
- Awaited
- Registrar
- Kfin Technologies Ltd.
- Minimum investment
- ₹14,526 (1 lot · 18 shares)
- Face value
- ₹1 per share
- Issue type
- Bookbuilding IPO
- Sale type
- Fresh capital cum OFS
- Fresh issue
- ₹200 Cr
- Offer for sale
- ₹740 Cr
- Listing at
- BSE, NSE
- Refunds
- 14 Aug 2026
- Shares credited
- 14 Aug 2026
- Promoter holding
- 44.89% before · 41.29% after
- Lead managers
- Kotak Mahindra Capital Co.Ltd., IIFL Capital Services Ltd., Jefferies India Pvt.Ltd., Motilal Oswal Investment Advisors Ltd.
Offer documents & links
Subscription by category
As of 12 Aug 2026, 1:22 pm.
Total subscription
49.22x
Full issue details
Details as published for this issue, read 11 Sept 2026, 4:57 am. Verify against the RHP before applying.
IPO Details
| IPO Date | 10 to 12 Aug, 2026 |
|---|---|
| Listed on | Mon, Aug 17, 2026 |
| Face Value | ₹ 1 per share |
| Price Band | ₹768 to ₹807 |
| Issue Price | ₹807 per share |
| Lot Size | 18 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹ 76.00 |
| Total Issue Size | 1,16,46,246 shares (agg. up to ₹ 940 Cr) |
|---|---|
| Fresh Issue | 24,80,246 shares (agg. up to ₹ 200 Cr) |
| Offer for Sale | 91,66,000 shares of ₹ 1 (agg. up to ₹ 740 Cr) |
| Share Holding Pre Issue | 11,27,59,750 shares |
| Share Holding Post Issue | 11,52,39,996 shares |
| BSE Script Code / NSE Symbol | 544866 / MOLBIO |
| ISIN | INE869T01028 |
IPO Timetable
- IPO Open
- Mon, Aug 10, 2026
- IPO Close
- Wed, Aug 12, 2026
- Allotment
- Thu, Aug 13, 2026
- Refund
- Fri, Aug 14, 2026
- Credit of Shares
- Fri, Aug 14, 2026
- Listing
- Mon, Aug 17, 2026
Issue Reservation
| Investor Category | Shares | % of Net Issue | % of Total Issue | Max Allottees |
|---|---|---|---|---|
| QIB | 58,12,862 | 50.00% | 49.91% | NA |
| − Anchor Investor | 34,87,717 | — | 29.95% | NA |
| − QIB (Ex. Anchor) | 23,25,145 | — | 19.96% | NA |
| NII (HNI) | 17,43,860 | 15.00% | 14.97% | NA |
| − bNII > ₹10L | 11,62,573 | — | 9.98% | 4,613 |
| − sNII < ₹10L | 5,81,287 | — | 4.99% | 2,306 |
| Retail | 40,69,005 | 35.00% | 34.94% | 2,26,055 |
| Preferential Reservations | ||||
| Employee | 20,519 | — | 0.18% | NA |
| Total | 1,16,46,246 | 100.00% | 100.00% | — |
Molbio Diagnostics IPO comprises a total issue size of 1,16,46,246 shares. The net offer to the public is 1,16,25,727 shares, after excluding 20,519 shares under a preferential allotment. Of the Net offer 58,12,862 (50.00%) are allocated to QIB , 17,43,860 (15.00%) allocated to NII 40,69,005 (35.00%) allocated to RII .
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹1,88,838 |
| S-HNI (Min) | 14 | 252 | ₹2,03,364 |
| S-HNI (Max) | 68 | 1224 | ₹9,87,768 |
| B-HNI (Min) | 69 | 1242 | ₹10,02,294 |
Investors can bid for a minimum of 18 shares and in multiples thereof.
IPO Subscription Details
IPO Anchor Investors
| Bid Date | Fri, Aug 7, 2026 |
|---|---|
| Shares Offered | 34,87,717 |
| Anchor Portion (₹ Cr.) | 281.46 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Sep 11, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Nov 10, 2026 |
Molbio Diagnostics IPO raises ₹ 281.46 crore from anchor investors . Molbio Diagnostics IPO Anchor bid date is August 7, 2026 .
IPO Anchor Investors List
Investor Category Reservations
| Category | Limit | Cut-off |
|---|---|---|
| RII | Up to ₹2 Lakhs | Yes |
| sNII | ₹2 Lakhs – ₹10 Lakhs | No |
| bNII | Above ₹10 Lakhs | No |
| Employee (EMP) | Up to ₹5 Lakhs | Yes |
| Employee + RII/NII | Up to ₹5Lakhs (EMP) + RII/NII limits | Yes (EMP/RII) |
About Molbio Diagnostics Ltd.
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.
Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities.
The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics.
As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.
Strengths
Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
Strong R&D capabilities supported by an extensive global patent portfolio.
Scalable business model with recurring revenues from diagnostic test kits.
Global presence across 90+ countries with strong government and institutional customer base.
Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.
Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.
Company Financials (Restated)
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total Income | 1,455.17 | 1,027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| NET Worth | 1,144.68 | 952.95 | 807.94 |
| Reserves and Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
| Amount in ₹ Crore |
Molbio Diagnostics Ltd.'s revenue increased by 42% and profit after tax (PAT) rose by 18% between the financial year ending with March 31, 2026 and March 31, 2025.
Recently Listed IPOs in Medical Equipment & Supplies
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Fabtech Technologies Ltd. | Mainboard | ₹230.30 Cr | ₹191 | 13.32 | ₹182.40 | -4.50% | ₹147.42 |
| Q-Line Biotech Ltd. | SME | ₹214.48 Cr | ₹343 | 20.82 | ₹474.60 | +38.37% | ₹714.95 |
| Earkart Ltd. | SME | ₹49.26 Cr | ₹135 | 20.48 | ₹142.25 | +5.37% | ₹138.00 |
| Galaxy Medicare Ltd. | SME | ₹22.31 Cr | ₹54 | 19.01 | ₹51.30 | -5.00% | ₹16.55 |
View More »
IPO Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space. | 105.54 |
| 2 | Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and | 72.28 |
| 3 | General Corporate Purposes | 9.47 |
| 4 | Issue Expenses | 59.54 |
| Total | 246.83 |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Key Performance Indicator (KPI)
| KPI | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| ROE | 15.59% | 16.20% |
| ROCE | 17.55% | 20.98% |
| RoNW | 14.55% | 15.23% |
| PAT Margin | 11.28% | 13.48% |
| EBITDA Margin | 22.56% | 24.97% |
| NAV | 101.51 | 84.51 |
| Price to Book Value | — | 9.55 |
Check IPO Peer Comparison here.
IPO Valuation
| Valuation Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 14.56 | 14.24 |
| P/E (x) | 55.43 | 56.67 |
| Market Cap at Offer Price | ₹9,100Cr. | ₹12,004.55 Cr |
Disclaimer
The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2026 available in RHP.
The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2026 available in RHP.
Shareholding Structure
| Category | Pre IPO | Post IPO |
|---|---|---|
| Promoter and Promoter Group | 44.89% | 41.29% |
| Public | 55.11% | 58.71% |
| Total | 100% | 100% |
Company Promoters: Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP.
.etc-Rk5dbsnpfiv5viur9flb:not(.show) table tbody > tr:nth-child(n + 6) { display: none; }
Offer For Sale - Selling Shareholders
| Name | Category | No. of Shares Offered | Amount (₹ cr.) |
|---|---|---|---|
| Exxora Trading LLP | Promoter | 18,11,000 | 146.12 |
| India Business Excellence Fund III | Corporate | 10,00,000 | 80.69 |
| Chandrasekhar Bhaskaran Nair | Promoter | 12,21,000 | 98.52 |
| Gopalkrishna Mangalore Kini | Other | 11,25,000 | 90.77 |
| J.Guru Dutt | Other | 9,02,000 | 72.78 |
| Gopalakrishna Sampathgiri | Other | 9,02,000 | 72.78 |
| Sangeetha M.Kini | Other | 4,52,000 | 36.47 |
| M.A.Usha Rani | Other | 4,51,000 | 36.39 |
| M.A.Rohit | Other | 2,48,000 | 20.01 |
| Abdul Qadir Mohamed Theruvath | Other | 48,000 | 3.87 |
| Chewbacca Services Ltd. | Corporate | 1,93,000 | 15.57 |
| M.Ganesh Kamath | Other | 17,000 | 1.37 |
| M.A.Sharath | Other | 2,02,000 | 16.30 |
| Shaheeda Abdul Kader | Other | 97,000 | 7.83 |
| Shruthi G.Kini | Other | 2,26,000 | 18.24 |
| Sujay Ltd. | Corporate | 1,93,000 | 15.57 |
| Vivek Devaraj | Other | 78,000 | 6.29 |
| Total | — | 91,66,000 | 739.57 |
Molbio Diagnostics IPO Recommendations
| Review By | Subscribe | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Brokers | 9 | 1 | 1 | 0 |
| Members | 0 | 0 | 0 | 0 |
IPO Subscription Status
| Category | Subscription (x) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB (Ex Anchor) | 186.39 | 23,25,146 | 43,33,82,148 |
| NII | 49.80 | 17,43,859 | 8,68,40,604 |
| bNII (> ₹10L) | 50.82 | 11,62,573 | 5,90,76,594 |
| sNII (< ₹10L) | 47.76 | 5,81,286 | 2,77,64,010 |
| Retail | 12.97 | 40,69,004 | 5,27,70,906 |
| Employee | 13.28 | 20,520 | 2,72,466 |
| Total | 70.27 | 81,58,529 | 57,32,66,124 |
The Molbio Diagnostics IPO is subscribed 70.27 times on August 12, 2026 6:52:45 PM (Day 3). The public issue subscribed 12.97 times in the retail category, 186.39 times in the QIB category, and 49.80 times in the NII category. Check Day by Day Subscription Details (Live Status)
Reload
Total Applications: 26,85,091
IPO Expenses
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees payable to the BRLMs | 21.07 |
| 2 | Brokerage, selling commission, bidding charges, processing fees and bidding charges for the Members of the Syndicate, Registered Brokers, SCSBs, RTAs and CDPs, sponsor bank(s) | 2.06 |
| 3 | Fees payable to Registrar to the Offer | 0.43 |
| 4 | Printing and stationery expenses | 0.99 |
| 5 | Advertising and marketing expenses | 6.38 |
| 6 | Listing fees, SEBI fees, BSE and NSE processing fees, book-building software fees, and other regulatory expenses | 6.22 |
| 7 | Fees payable to the advisors and other parties to the Offer namely auditors, independent chartered accountant, independent chartered engineer, IPR consultant, Project Report Provider, practicing company secretary and others | 12.17 |
| 8 | Fees payable to legal counsel | 7.89 |
| 9 | Miscellaneous | 2.35 |
| Total | 59.54 |
Listing Day Trading Information
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹ 807.00 | ₹ 807.00 |
| Open | ₹ 980.00 | ₹ 980.00 |
| Low | ₹ 925.80 | ₹ 926.35 |
| High | ₹ 1,064.85 | ₹ 1,064.75 |
| Last Trade | ₹ 1,036.30 | ₹ 1,041.70 |
Check IPO Performance…
IPO Registrar
Kfin Technologies Ltd.
040-79615565
molbio.ipo@kfintech.com
IPO Lead Manager(s)
Kotak Mahindra Capital Co.Ltd.
IIFL Capital Services Ltd.
Jefferies India Pvt.Ltd.
Motilal Oswal Investment Advisors Ltd.
Contact Details
Molbio Diagnostics Ltd. Address
Plot No. L-46
Phase II-D, Verna Industrial Area
Verna, Salcete
South Goa, Goa , 403722
8326724888
investors@molbiodiagnostics.com
Molbio Diagnostics IPO in the news
Recent coverage in the financial press. Headlines are the publishers' own; verify details with the RHP.
Molbio Diagnostics share price hits 20% upper circuit, jumps 87% from IPO price
TradingView · 10 Sept 2026
Molbio Diagnostics hits 20% upper circuit on heavy volume; up 35% in 2 days
Business Standard · 10 Sept 2026
Molbio Diagnostics share price hits 20% upper circuit, jumps 87% from IPO price
Livemint · 10 Sept 2026
Molbio Diagnostics shares rally 30% in 2 days, jump 80% since debut. What lies ahead?
economictimes.com · 10 Sept 2026
Molbio Diagnostics Q1FY27 net profit up 523% to ₹52.7 crore on deferred exports
scanx.trade · 9 Sept 2026
Molbio swings to Rs 52.7 crore Q1 profit after Rs 940 crore IPO
app.dealroom.co · 7 Sept 2026
Newly-listed Molbio Diagnostics posts Rs 52.7 cr profit in Q1
ET HealthWorld · 7 Sept 2026
Results Review 📌 ▶️Malbio Diagnostics: - लिस्टिंग के बाद पहले नतीजे बेहद शानदार - घाटे से मुनाफे में आई कंपनी - 807 की IPO प्राइस से शेयर आज 1160 पर #ResultReview #MolbioDiagnostics #Molbio #IPO #StockMarket #ShareM
facebook.com · 7 Sept 2026
